India, May 4 -- image credit- freepik

The University of Oxford, through Oxford University Innovation (OUI), and the Serum Institute of India (SII), have entered into a licence agreement to support the development and manufacture of the new malaria vaccine candidate R78C, based on two Plasmodium falciparum blood-stage antigens (RIPR and CyPRA), for use in clinical settings.

The agreement grants SII a non-exclusive, worldwide licence to develop R78C as part of a next-generation multi-stage malaria vaccine - a major step designed to target the parasite at multiple points in its lifecycle, with the aim of improving efficacy and durability of protection.

The collaboration builds on a longstanding association between Oxford and Serum Institu...